Cellestus Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 10-01-2025
- Paid Up Capital ₹ 0.10 M
as on 10-01-2025
- Company Age 10 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.70 M
as on 10-01-2025
- Revenue 12.99%
(FY 2021)
- Profit 9.70%
(FY 2021)
- Ebitda 534.80%
(FY 2021)
- Net Worth 8.68%
(FY 2021)
- Total Assets 20.69%
(FY 2021)
About Cellestus Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.70 M.
Kiran Devi and Manoj Shahi serve as directors at the Company.
- CIN/LLPIN
U24232HP2014PTC000736
- Company No.
000736
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Jul 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Himachal Pradesh
Industry
Company Details
- Location
Solan, Himachal Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Cellestus Pharmaceuticals Private Limited offer?
Cellestus Pharmaceuticals Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Antacid Drugs, Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules, Antibiotic Injection, Cardiovascular Drugs & Medication, Kidney Drugs, Multivitamin Syrup & Drops.
Who are the key members and board of directors at Cellestus Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kiran Devi  | Director | 31-Jul-2018 | Current |
| Manoj Shahi | Director | 24-Jul-2014 | Current |
Financial Performance of Cellestus Pharmaceuticals.
Cellestus Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 12.99% increase. The company also saw a slight improvement in profitability, with a 9.7% increase in profit. The company's net worth moved up by a moderate rise of 8.68%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cellestus Pharmaceuticals?
In 2021, Cellestus Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 08 Jul 2024 | ₹1.70 M | Open |
Others Creation Date: 28 Aug 2019 | ₹1.00 M | Open |
How Many Employees Work at Cellestus Pharmaceuticals?
Unlock and access historical data on people associated with Cellestus Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cellestus Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cellestus Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
